Nothing Special   »   [go: up one dir, main page]

AR094740A1 - ANTIADHESION OF LEUKOCYTES TO MITIGATE POTENTIAL ADVERSE EVENTS CAUSED BY CD3 SPECIFIC UNION DOMAINS - Google Patents

ANTIADHESION OF LEUKOCYTES TO MITIGATE POTENTIAL ADVERSE EVENTS CAUSED BY CD3 SPECIFIC UNION DOMAINS

Info

Publication number
AR094740A1
AR094740A1 ARP140100416A ARP140100416A AR094740A1 AR 094740 A1 AR094740 A1 AR 094740A1 AR P140100416 A ARP140100416 A AR P140100416A AR P140100416 A ARP140100416 A AR P140100416A AR 094740 A1 AR094740 A1 AR 094740A1
Authority
AR
Argentina
Prior art keywords
cells
events caused
antiadhesion
leukocytes
adverse events
Prior art date
Application number
ARP140100416A
Other languages
Spanish (es)
Inventor
Zugmaier Gerhard
Klinger Matthias
Hoffmann Patrick
Naegele Virginie
P Dopfer Elaine
Kufer Peter
Nagorsen Dirk
Scheele Jrgen
Original Assignee
Amgen Res (Munich) Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Res (Munich) Gmbh filed Critical Amgen Res (Munich) Gmbh
Publication of AR094740A1 publication Critical patent/AR094740A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Endocrinology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)

Abstract

Un compuesto que disminuye o inhibe la unión de células T de mamífero con las células endoteliales de mamífero para su uso en un método de profilaxis y/o mejora y/o tratamiento de los eventos clínicos adversos causados por una terapia que comprende el redireccionamiento de las células T contra células blanco en un paciente. También se contemplan métodos de tratamiento de pacientes que sufren, o que tienen el riesgo, de sufrir de eventos clínicos adversos causados por una terapia que comprende el redireccionamiento de células T contra células blanco. Conjunto de elementos; composición farmacéutica; dominio de unión a CD3 (antígeno de célula T); ácido nucleico; células.A compound that decreases or inhibits the binding of mammalian T cells with mammalian endothelial cells for use in a method of prophylaxis and / or improvement and / or treatment of adverse clinical events caused by a therapy comprising the redirection of T cells against white cells in a patient. Methods of treating patients who suffer, or who are at risk, suffer from adverse clinical events caused by a therapy that includes the redirection of T cells against white cells are also contemplated. Set of elements; pharmaceutical composition; CD3 binding domain (T cell antigen); nucleic acid; cells.

ARP140100416A 2013-02-08 2014-02-07 ANTIADHESION OF LEUKOCYTES TO MITIGATE POTENTIAL ADVERSE EVENTS CAUSED BY CD3 SPECIFIC UNION DOMAINS AR094740A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361762718P 2013-02-08 2013-02-08
US201361811526P 2013-04-12 2013-04-12

Publications (1)

Publication Number Publication Date
AR094740A1 true AR094740A1 (en) 2015-08-26

Family

ID=50231117

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140100416A AR094740A1 (en) 2013-02-08 2014-02-07 ANTIADHESION OF LEUKOCYTES TO MITIGATE POTENTIAL ADVERSE EVENTS CAUSED BY CD3 SPECIFIC UNION DOMAINS

Country Status (13)

Country Link
US (2) US9688760B2 (en)
EP (2) EP3760210A1 (en)
JP (2) JP6567425B2 (en)
AR (1) AR094740A1 (en)
AU (2) AU2014214020B2 (en)
CA (1) CA2898032C (en)
ES (1) ES2811764T3 (en)
HK (1) HK1216996A1 (en)
JO (1) JO3529B1 (en)
MX (2) MX2019012421A (en)
TW (2) TW201929865A (en)
UY (1) UY35313A (en)
WO (1) WO2014122251A2 (en)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10191034B2 (en) * 2011-04-28 2019-01-29 Amgen Research (Munich) Gmbh Dosage regimen for administrating a CD19×CD3 bispecific antibody to patients at risk for potential adverse effects
US20130058936A1 (en) 2011-08-23 2013-03-07 Peter Bruenker Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
KR20150064068A (en) 2012-10-08 2015-06-10 로슈 글리카트 아게 FC-FREE ANTIBODIES COMPRISING TWO Fab-FRAGMENTS AND METHODS OF USE
US9486475B2 (en) * 2013-02-08 2016-11-08 Amgen Research (Munich) Gmbh PPS for the prevention of potential adverse effects caused by CD3 specific binding domains
JO3529B1 (en) * 2013-02-08 2020-07-05 Amgen Res Munich Gmbh Anti-leukocyte adhesion for the mitigation of potential adverse events caused by CD3-specific binding domains
EP2961771B1 (en) 2013-02-26 2020-01-01 Roche Glycart AG Bispecific t cell activating antigen binding molecules specific to cd3 and cea
MX2015010350A (en) 2013-02-26 2015-10-29 Roche Glycart Ag Bispecific t cell activating antigen binding molecules.
US10101247B2 (en) * 2013-07-19 2018-10-16 Rarecyte, Inc. Solution and method for adhering suspension components to a substrate
DK3736292T3 (en) 2013-12-17 2024-07-22 Genentech Inc Anti-CD3 Antibodies and Methods of Use
EP3531133B1 (en) 2014-05-30 2023-08-23 Amgen Research (Munich) GmbH Risk-stratification of b-precursor acute lymphoblastic leukemia patients
PL3608337T3 (en) 2014-08-04 2024-07-22 F. Hoffmann-La Roche Ag Bispecific t cell activating antigen binding molecules
CR20170095A (en) 2014-09-12 2017-07-19 Genentech Inc ANTI-CLL-1 ANTIBODIES AND IMMUNOCATE PLAYERS RECIPROCAL REFERENCES WITH RELATED APPLICATIONS
MY192999A (en) 2014-11-20 2022-09-20 Hoffmann La Roche Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists
EP3747905A1 (en) 2014-11-20 2020-12-09 F. Hoffmann-La Roche AG Common light chains and methods of use
TW201718647A (en) 2015-06-16 2017-06-01 建南德克公司 Anti-CLL-1 antibodies and methods of use
AR105026A1 (en) 2015-06-16 2017-08-30 Genentech Inc ANTIBODIES MATURED BY AFFINITY AND HUMANIZED FOR FcRH5 AND METHODS FOR USE
US11890301B2 (en) * 2015-08-28 2024-02-06 The Trustees Of The University Of Pennsylvania Methods and compositions for cells expressing a chimeric intracellular signaling molecule
CN106554414B (en) * 2015-09-18 2019-04-23 上海科济制药有限公司 Anti- CD19 human antibody and the immune effector cell for targeting CD19
AR106188A1 (en) 2015-10-01 2017-12-20 Hoffmann La Roche ANTI-CD19 HUMANIZED HUMAN ANTIBODIES AND METHODS OF USE
AU2016329111A1 (en) 2015-10-02 2018-02-08 F. Hoffmann-La Roche Ag Bispecific anti-CEAXCD3 T cell activating antigen binding molecules
US10101248B1 (en) * 2015-12-02 2018-10-16 Rarecyte, Inc. Solution and method for adhering suspension components to a substrate
CN108290954B (en) 2015-12-09 2022-07-26 豪夫迈·罗氏有限公司 Use of type II anti-CD 20 antibodies to reduce anti-drug antibody formation
AR107303A1 (en) 2016-01-08 2018-04-18 Hoffmann La Roche METHODS OF TREATMENT OF POSITIVE CANCER FOR ACE USING ANTAGONISTS OF AXISION TO AXIS PD-1 AND ANTI-ACE / ANTI-CD3, USE, COMPOSITION, KIT
PE20231511A1 (en) 2016-03-22 2023-09-26 Hoffmann La Roche BISPECIFIC T CELL MOLECULES ACTIVATED BY PROTEASES THAT BIND SPECIFICALLY TO FOLATE RECEPTOR 1 (FOLR1) AND CD3
JP6225321B1 (en) * 2016-08-31 2017-11-08 王子ホールディングス株式会社 Method for producing polysulfate pentosan
WO2018043667A1 (en) 2016-08-31 2018-03-08 王子ホールディングス株式会社 Production method for acidic xylooligosaccharide, and acidic xylooligosaccharide
CN109843926B (en) 2016-09-30 2023-01-20 豪夫迈·罗氏有限公司 Bispecific antibodies against CD3
CA3042435A1 (en) 2016-11-15 2018-05-24 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
AU2018219226A1 (en) 2017-02-07 2019-08-15 Seattle Children's Hospital (dba Seattle Children's Research Institute) Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
EP3589295B1 (en) 2017-02-28 2024-09-11 Endocyte, Inc. Compositions and methods for car t cell therapy
JP6281659B1 (en) 2017-02-28 2018-02-21 王子ホールディングス株式会社 Polysulfate pentosan, pharmaceutical composition and anticoagulant
JP2020517259A (en) 2017-04-19 2020-06-18 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム Immune cells expressing engineered antigen receptors
EP3632451A4 (en) 2017-05-31 2021-03-10 Oji Holdings Corporation Moisturizing topical preparation
KR102678054B1 (en) 2017-09-12 2024-06-24 오지 홀딩스 가부시키가이샤 Method for producing polypentosan sulfate and polypentosan sulfate
AU2018336791A1 (en) 2017-09-19 2020-03-12 Massachusetts Institute Of Technology Compositions for chimeric antigen receptor T cell therapy and uses thereof
CA3086301A1 (en) 2017-12-20 2019-06-27 Oji Holdings Corporation Pentosan polysulfate and medicine containing pentosan polysulfate
CN112055595A (en) 2018-01-22 2020-12-08 恩多塞特公司 Methods of use of CAR T cells
AR115360A1 (en) 2018-02-08 2021-01-13 Genentech Inc ANTIGEN BINDING MOLECULES AND METHODS OF USE
AU2019346335B2 (en) 2018-09-28 2024-07-25 Massachusetts Institute Of Technology Collagen-localized immunomodulatory molecules and methods thereof
WO2020221792A1 (en) * 2019-04-30 2020-11-05 Amgen Research (Munich) Gmbh Means and methods of treating burkitt lymphoma or leukemia
JOP20210298A1 (en) 2019-05-14 2023-01-30 Provention Bio Inc Methods and compositions for preventing type 1 diabetes
JP2022538974A (en) 2019-06-26 2022-09-07 マサチューセッツ インスチテュート オブ テクノロジー Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
WO2021061648A1 (en) 2019-09-23 2021-04-01 Massachusetts Institute Of Technology Methods and compositions for stimulation of endogenous t cell responses
CR20230210A (en) 2019-12-13 2023-06-14 Genentech Inc Anti-ly6g6d antibodies and methods of use
AU2021236145A1 (en) 2020-03-10 2022-09-22 Dana-Farber Cancer Institute, Inc. Methods for generating engineered memory-like NK cells and compositions thereof
CA3173981A1 (en) 2020-03-10 2021-09-16 Massachusetts Institute Of Technology Compositions and methods for immunotherapy of npm1c-positive cancer
US20210340524A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
WO2021221782A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Chimeric antigen receptor-targeting ligands and uses thereof
BR112022025381A2 (en) 2020-06-11 2023-01-24 Provention Bio Inc METHODS AND COMPOSITIONS TO PREVENT TYPE 1 DIABETES
AU2021291011A1 (en) 2020-06-19 2023-01-05 F. Hoffmann-La Roche Ag Antibodies binding to CD3 and CD19
CN112521513B (en) * 2020-12-15 2021-08-24 青岛西凯生物技术有限公司 Chimeric Antigen Receptor (CAR) targeting CD19 and application thereof
CN113637087A (en) * 2021-07-09 2021-11-12 上海易慕峰生物科技有限公司 Chimeric receptor and cell for improving safety of cell immunotherapy
WO2023081715A1 (en) 2021-11-03 2023-05-11 Viracta Therapeutics, Inc. Combination of car t-cell therapy with btk inhibitors and methods of use thereof
WO2024206166A1 (en) * 2023-03-31 2024-10-03 Memorial Sloan-Kettering Cancer Center Microenvironment actuated t-cells and uses thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2689848A (en) 1951-02-06 1954-09-21 Wander Ag Dr A Salts of sulfuric acid esters of xylan
DE3856559T2 (en) 1987-05-21 2004-04-29 Micromet Ag Multifunctional proteins with predetermined objectives
US5605938A (en) 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
CA2140933A1 (en) 1992-08-21 1994-02-22 Paula M. Jardieu Method for treating an lfa-1 mediated disorder
US7112324B1 (en) 1998-04-21 2006-09-26 Micromet Ag CD 19×CD3 specific polypeptides and uses thereof
US7635472B2 (en) 2003-05-31 2009-12-22 Micromet Ag Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
CA2478458A1 (en) 2004-08-20 2006-02-20 Michael Panzara Treatment of pediatric multiple sclerosis
US8007796B2 (en) 2005-12-16 2011-08-30 Micromet Ag Means and methods for the treatment of tumorous diseases
PT2016102E (en) 2006-05-03 2012-05-15 Us Gov Health & Human Serv Chimeric t cell receptors and related materials and methods of use
EP2815764A1 (en) * 2006-06-14 2014-12-24 Macrogenics, Inc. Methods for the treatment of autoimmune disorders using monoclonal antibodies with reduced toxicity
WO2008107906A1 (en) 2007-03-06 2008-09-12 Alembic Limited Process for the preparation of pentosan polysulfate or salts thereof
US20100183615A1 (en) 2007-04-03 2010-07-22 Micromet Ag Cross-species-specific bispecific binders
AU2008234020B2 (en) 2007-04-03 2013-02-07 Amgen Research (Munich) Gmbh Cross-species-specific CD3-epsilon binding domain
SG10201808730VA (en) * 2007-04-03 2018-11-29 Amgen Res Munich Gmbh Cross-species-specific binding domain
US20090047243A1 (en) * 2007-07-17 2009-02-19 Richard Rickles Combinations for the treatment of b-cell proliferative disorders
TW200920381A (en) * 2007-07-17 2009-05-16 Combinatorx Inc Treatments of B-cell proliferative disorders
JP2010535776A (en) * 2007-08-10 2010-11-25 ワイズセラピューティックス株式会社 Regulation of immune response by administration of roxithromycin or its derivatives
US8026343B2 (en) 2008-08-08 2011-09-27 Dinona Inc. Antibody modulating the differentiation and function of dendritic cells via binding intercellular adhesion molecule-1 and use thereof
SG194398A1 (en) * 2008-10-01 2013-11-29 Amgen Res Munich Gmbh Cross-species-specific psmaxcd3 bispecific single chain antibody
PT2493503E (en) * 2009-10-27 2015-11-12 Amgen Res Munich Gmbh Dosage regimen for administering a cd19xcd3 bispecific antibody
DK2632954T4 (en) * 2010-10-27 2021-08-09 Amgen Res Munich Gmbh MEDICINES AND METHODS FOR THE TREATMENT OF DLBCL
LT2637670T (en) * 2010-11-10 2017-05-25 Amgen Research (Munich) Gmbh Prevention of adverse effects caused by cd3 specific binding domains
CN103442768A (en) * 2011-01-18 2013-12-11 宾夕法尼亚大学董事会 Compositions and methods for treating cancer
US10191034B2 (en) * 2011-04-28 2019-01-29 Amgen Research (Munich) Gmbh Dosage regimen for administrating a CD19×CD3 bispecific antibody to patients at risk for potential adverse effects
US9682143B2 (en) * 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
CN102875685B (en) 2012-09-29 2013-12-25 郑骏年 Chimeric antigen receptor hFVIIL-CD8-OX40-CD3zeta and application thereof
US9486475B2 (en) * 2013-02-08 2016-11-08 Amgen Research (Munich) Gmbh PPS for the prevention of potential adverse effects caused by CD3 specific binding domains
JO3529B1 (en) * 2013-02-08 2020-07-05 Amgen Res Munich Gmbh Anti-leukocyte adhesion for the mitigation of potential adverse events caused by CD3-specific binding domains

Also Published As

Publication number Publication date
US11084876B2 (en) 2021-08-10
EP2953630B1 (en) 2020-07-01
EP2953630A2 (en) 2015-12-16
TW201442714A (en) 2014-11-16
TWI704920B (en) 2020-09-21
JP6933684B2 (en) 2021-09-08
AU2014214020A1 (en) 2015-07-30
CA2898032C (en) 2021-06-15
MX368842B (en) 2019-10-18
WO2014122251A2 (en) 2014-08-14
AU2014214020B2 (en) 2018-11-15
HK1216996A1 (en) 2016-12-16
WO2014122251A3 (en) 2014-10-02
JP2016514090A (en) 2016-05-19
EP3760210A1 (en) 2021-01-06
JO3529B1 (en) 2020-07-05
TW201929865A (en) 2019-08-01
AU2019200841B2 (en) 2020-08-13
JP2019178142A (en) 2019-10-17
US9688760B2 (en) 2017-06-27
AU2019200841A1 (en) 2019-02-28
MX2019012421A (en) 2022-10-13
US20140227272A1 (en) 2014-08-14
JP6567425B2 (en) 2019-08-28
CA2898032A1 (en) 2014-08-14
ES2811764T3 (en) 2021-03-15
MX2015009922A (en) 2015-09-25
UY35313A (en) 2014-08-29
US20170327581A1 (en) 2017-11-16

Similar Documents

Publication Publication Date Title
AR094740A1 (en) ANTIADHESION OF LEUKOCYTES TO MITIGATE POTENTIAL ADVERSE EVENTS CAUSED BY CD3 SPECIFIC UNION DOMAINS
CO2020006009A2 (en) Methods of using ehmt2 inhibitors to treat or prevent blood disorders
CY1122060T1 (en) COMBINATION THERAPEUTIC USE OF ANTIBODIES AND ENDOGLYCOSIDASES
CY1124307T1 (en) PHARMACEUTICAL COMPOSITION, METHODS OF THERAPY AND USES THEREOF
CL2017002481A1 (en) Combination therapy of fibroblast growth factor receptor (fgfr) / progamed death 1 (pd 1) for cancer treatment
EA201491011A1 (en) METHODS OF TREATMENT BY MEANS OF THE GAMMA INTERFERON INHIBITOR
EA201890725A1 (en) PHARNESIDE X-RECEPTOR AGONISTS AND THEIR APPLICATION
EA201790195A1 (en) METHODS OF TREATING CANCER WITH THE USE OF TIGIT INHIBITORS AND ANTI-CANCER AGENTS
PH12019500439A1 (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
UA118453C2 (en) Modulation of tumor immunity
EA201791007A3 (en) COMPOUNDS AND THEIR APPLICATIONS FOR MODULATION OF HEMOGLOBIN
EA201591427A1 (en) COMPOUNDS AND THEIR APPLICATIONS FOR MODULATION OF HEMOGLOBIN
EA201591426A1 (en) COMPOUNDS AND THEIR APPLICATIONS FOR MODULATION OF HEMOGLOBIN
MX2021000898A (en) METHODS FOR TREATING PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (heFH).
PE20160538A1 (en) MONOCLONAL ANTIBODIES OPTIMIZED AGAINST THE TISSUE FACTOR PATH INHIBITOR (TFPI)
CU20110236A7 (en) COMPLETELY HUMAN MONOCLONAL ANTIBODIES AGAINST THE INHIBITOR OF THE TISSULAR FACTOR ROUTE (TFPI)
RS54525B1 (en) Means and methods for treating dlbcl
EA201300133A1 (en) PHARMACEUTICAL COMPOSITION AND METHOD FOR THE TREATMENT OF OBESITY ASSOCIATED WITH METABOLIC DISORDERS AND DEPENDENCE ON PSYCHOACTIVE SUBSTANCES
EA201592203A1 (en) METHODS OF TREATMENT OF Taupathy
AR101740A1 (en) COMBINATION AND COMPOSITION THERAPY
BR112015010039A2 (en) treatment of cancer with pomalidomide in an individual with renal dysfunction
BR112013028420A2 (en) multiple myeloma treatment
EA201991511A1 (en) GREMLIN-1 CRYSTAL STRUCTURE AND AN INHIBITING ANTIBODY
BR112015027477A8 (en) bolus, its uses, and kit
EA201692481A1 (en) COMBINATION CONTAINING GLUCOCORTICOID AND EDO-S101

Legal Events

Date Code Title Description
FB Suspension of granting procedure